Skip to main content

Table 1 Patient demographics and disease characteristics at baseline

From: Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study

 

KRASPRO analysis set

PRO analysis set

WT KRAS(n = 76)

MT KRAS(n = 54)

Overall (n = 137)

Sex, n (%)

  Male

61 (80)

29 (54)

95 (69)

  Female

15 (20)

25 (46)

42 (31)

Race/ethnicity, n (%)

  White/Caucasian

73 (96)

53 (98)

133 (97)

  Black/African American

2 (3)

0 (0)

2 (1)

  Hispanic/Latino

0 (0)

1 (2)

1 (1)

  Japanese

1 (1)

0 (0)

1 (1)

Median age, years (range)

63.5 (21–84)

65.0 (37–80)

64.0 (21–84)

Age group, n (%)

  <65 years

40 (53)

26 (48)

71 (52)

  ≥65 years

36 (47)

28 (52)

66 (48)

  <75 years

71 (93)

44 (81)

121 (88)

  ≥75 years

5 (7)

10 (19)

16 (12)

Primary tumour type, n (%)

  Colon cancer

43 (57)

36 (67)

82 (60)

  Rectal cancer

33 (43)

18 (33)

55 (40)

Number of metastatic sites, n (%)

  1

33 (43)

23 (43)

63 (46)

  2

22 (29)

19 (35)

41 (30)

  ≥3

21 (28)

12 (22)

33 (24)

Location of metastatic sites, n (%)

  Liver only

28 (37)

15 (28)

46 (34)

  Liver plus other sites

35 (46)

25 (46)

60 (44)

  Other sites only

13 (17)

14 (26)

31 (23)

ECOG performance status, n (%)

  0

43 (57)

30 (56)

80 (58)

  1

30 (39)

20 (37)

50 (36)

  2

3 (4)

4 (7)

7 (5)

Mean (SD) PRO scores

  EQ-5D health state index

0.81 (0.22)

0.80 (0.22)

0.81 (0.22)

  EQ-5D overall health rating

71.7 (20.1)

71.9 (19.6)

72.5 (19.8)

  QLQ-C30 global health status

64.4 (22.5)

65.1 (22.8)

65.8 (22.5)

  1. ECOG Eastern Oncology Group; PRO patient-reported outcome.